We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Protein Biomarker Discovered for Uterine Cancer

By LabMedica International staff writers
Posted on 05 May 2015
A new biomarker has been discovered which makes it possible to identify women with uterine cancer who have a high risk of recurrence.

Endometrial cancer of the uterus is the most common form of gynecologic cancer in Europe and North America and the treatment primarily consists of removing the uterus and in some cases offering chemotherapy if the risk of recurrence is deemed high. More...


Scientists at Uppsala University (Sweden) and their colleagues conducted a study based on samples collected from 500 women who were diagnosed with uterine cancer between the years 1981 and 2007. Tissue microarrays (TMA) were constructed from formalin-fixed, paraffin-embedded (FFPE) primary tumors derived from hysterectomy specimens. Duplicate 1.0 mm diameter cores from each donor block were assembled into a recipient TMA block using the Beecher Manual Tissue Arrayer MTA-1 (Estigen OÜ; Tartu, Estonia).

Automated immunohistochemistry (IHC) was performed using a LabVision Autostainer 480S (Thermo Fisher Scientific; Runcorn, UK). Stained slides were scanned using an Aperio ScanScope XT Slide Scanner (Aperio Technologies; Vista, CA, USA). The l-asparaginase (ASRGL1) protein was identified as an endometrial carcinoma biomarker candidate. ASRGL1 expression was immunohistochemically evaluated. The protein ASRGL1 is an enzyme that normally exists in healthy cells of the uterus.

The investigators found that patients who had entirely or partially lost ASRGL1 in the tumor cells had a much higher risk of the cancer recurring and dying from the disease, while patients with sustained high levels of ASRGL1 had a much lower risk of recurrence. The study also shows that ASRGL1 is an independent prognostic factor, even after compensating for other risk factors such as tumor stage and tumor grade.

Per-Henrik Edqvist, PhD, the lead author of the study, said, “'I view the results as a first step towards personal treatment of uterine cancer. Today, 10% to 15% of the patients suffer recurrences, even though they were considered low risk patients according to classic diagnostics. By using ASRGL1, the chance of identifying such hidden high-risk patients and offer them more aggressive treatment after their operation increases.” The study was published on April 6, 2015, in the journal Gynecologic Oncology.

Related Links:

Uppsala University
Estigen
Thermo Fisher Scientific
Aperio Technologies



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.